18F FACBC an innovative imaging agent for the diagnosis of prostate cancer: a Phase III evaluation in recurrent prostate cancer

在前列腺癌的情况下，需要更好的诊断成像方法。目前的方法既不灵敏，也不够特异，不能积极地指导前列腺癌患者的治疗。增加细胞代谢和与之相关的氨基酸转运增加是恶性肿瘤生长和增殖的必要条件。FACBC注射剂中的活性物质是一种人工合成的L-亮氨酸类似物，根据临床前研究，该类似物已被证明在癌细胞中高度蓄积。氨基酸摄取和细胞整体新陈代谢之间存在着密切的关系。这笔赠款将支持在男性复发性前列腺癌患者中进行的第三阶段临床研究，试图证明一种新型正电子发射断层扫描(PET)试剂：[18F]FACBC的疗效。独一无二的是，这将是第一个在英国单独进行的PET成像第三阶段研究。该项目将把7个世界级的临床中心与GE Healthcare结合在一起，进一步开发这种潜在的重要新显像剂。

In the case of prostate cancer there is a need for better diagnostic imaging methods. Current methods are neither sensitive nor specific enough to positively direct prostate cancer patient management.Increased cellular metabolism and an associated increase in amino acid transport is a requirement for the growth and proliferation of malignant tumours. The active substance in the [18]FACBC injection is a synthetic L-leucine analogue that has been shown to accumulate to a high degree in cancer cells based on preclinical studies. There is an established close relationship between amino acid uptake and overall cellular metabolism. This grant will support a Phase III clinical study in men with recurrent prostate cancer in an attempt to demonstrate efficacy of a novel Positron Emission Tomography (PET) agent: [18F]FACBC. Uniquely this will be the first Phase III study in PET imaging solely carried out in the UK. The project will bring 7 world class clinical centres together with GE Healthcare to further develop this potentially important new imaging agent.